Urolithin A: the postbiotic that rejuvenates your mitochondria

Urolithin A is a compound that has been accumulating scientific evidence for years. It is not manufactured in a laboratory like a conventional drug: it arises from the interaction between certain foods and intestinal bacteria. When we consume ellagitannins, found in foods such as pomegranate, walnuts, and berries, some bacteria in the microbiome convert them into urolithin A. The problem is that only 35 to 40 percent of people have the gut bacteria necessary to perform that conversion. The rest, no matter how healthy their diet is, do not obtain significant amounts of this compound from food alone.

What is mitophagy and why does it rejuvenate cells

To understand why this compound attracts so much scientific attention, it is first necessary to understand a process called mitophagy. Mitochondria are the organelles responsible for producing cellular energy, and like any biological machinery, they deteriorate over time. When damaged mitochondria accumulate, cells lose efficiency, inflammation increases, and aging accelerates.

Mitophagy is the mechanism that selectively identifies and removes defective mitochondria while preserving the healthy ones. It is not indiscriminate destruction: it is cellular quality control. Urolithin A activates this process in a remarkable way, and that is the starting point for understanding all of its other benefits. Everything that impacts aging also impacts mitochondria, and vice versa. This is why researchers see in this compound a systemic tool, not a partial solution.

Effects on the immune system

One of the most striking findings from clinical trials with urolithin A concerns its impact on the immune system of older adults. In a study with elderly subjects, just one month of supplementation produced measurable changes:

• Reduction in inflammatory markers such as C-reactive protein (CRP) and pro-inflammatory cytokines including TNF-alpha, IL-1, and IL-6.
• Increase in naive T cells, the unactivated lymphocytes that are essential for generating adaptive immune responses against new pathogens.
• Greater capacity of T cells to recognize and attack their targets.

This last point is particularly relevant for oncology. CAR-T cell therapies, which reprogram T lymphocytes from the patient to attack tumors, lose effectiveness with age because the ability to re-educate these cells declines. In vitro studies have suggested that urolithin A could improve the effectiveness of these therapies by restoring T cell functionality in older individuals.

A compound with broad effects

Mitochondria are present in virtually every tissue in the body, which means that any intervention acting through mitophagy will have widespread effects. In the scientific literature, this is described as a pleiotropic effect.

In the case of urolithin A, human studies have documented improvements in physical endurance capacity, VO2 max, and muscle health. Research in neurological tissue is ongoing, with hypotheses pointing to potential benefits in memory and cognitive function. While these have not yet been proven, the biological logic is coherent: if mitochondria function better in every cell, the brain benefits too.

This contrasts with the classical pharmacological model, which designs molecules to act on a single target. Longevity medicine increasingly points to interventions that address the underlying mechanisms of aging, and urolithin A is a concrete example of that approach.

Urolithin A as a postbiotic: eating to repair

Urolithin A belongs to the category of postbiotics: compounds that the microbiome produces by fermenting certain food nutrients. The underlying idea is remarkable. By consuming foods rich in ellagitannins, we are providing our gut bacteria with the raw material to manufacture molecules that activate cellular repair systems. In a sense, it is like taking a medicine that the body itself manufactures from what we eat.

This vision reflects the coevolution between humans and plants. We do not synthesize vitamin C and obtain it from food. Similarly, we depend on the microbiome to convert plant compounds into functional postbiotics. The diversity and richness of the gut bacterial flora largely determines how much urolithin A any given person can produce.

The microbiome can be modified. Diet, antibiotic use, and exposure to toxins continuously shape it. Maintaining a diverse bacterial flora through a varied diet rich in plant fiber is therefore a foundational strategy for those who want to maximize the endogenous production of this compound.

How to access urolithin A

For those who do not have the appropriate microbiota to convert ellagitannins into urolithin A, direct supplementation is the most evidence-supported route. The company Amazentis has led this area, being the first to commercialize urolithin A backed by clinical trials published in leading journals such as Cell.

For those who do have that metabolic capacity, consuming pomegranate, walnuts, berries, and other ellagitannin-rich sources while maintaining a rich and diverse microbiome can be sufficient to obtain meaningful benefits.

Conclusion

Urolithin A is a clear example of how modern science can identify the precise mechanism that makes certain foods healthy. Activating mitophagy, rejuvenating the immune system, and protecting mitochondria point to a systemic intervention on aging with a solid and growing clinical foundation.